Լևոդոպա (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Լևոդոպա" in Armenian language version.

refsWebsite

Global rank Armenian rank

38nih.gov

4^th place

3^rd place

30doi.org

2^nd place

4^th place

6semanticscholar.org

11^th place

428^th place

3web.archive.org

1^st place

3harvard.edu

18^th place

38^th place

2archive.org

6^th place

1q1medicare.com

low place

1drugs.com

399^th place

102^nd place

1inbrija.com

low place

1acorda.com

low place

1clinchem.org

low place

9,992^nd place

1sciencedaily.com

993^rd place

568^th place

1northwestern.edu

2,302^nd place

3,560^th place

1handle.net

102^nd place

2,318^th place

1laskerfoundation.org

low place

8,928^th place

1books.google.com

3^rd place

17^th place

1wisc.edu

1,045^th place

451^st place

acorda.com

ir.acorda.com

«Acorda Therapeutics Announces FDA Approval of INBRIJA™ (levodopa inhalation powder)». ir.acorda.com (կանադական անգլերեն). Վերցված է 2019-02-14-ին.

archive.org

Ito S, Kato T, Shinpo K, Fujita K (September 1984). «Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine». The Biochemical Journal. 222 (2): 407–11. doi:10.1042/bj2220407. PMC 1144193. PMID 6433900.
Knowles WS (March 1986). «Application of organometallic catalysis to the commercial production of L-DOPA». Journal of Chemical Education. 63 (3): 222. Bibcode:1986JChEd..63..222K. doi:10.1021/ed063p222.

books.google.com

Simuni T, Hurtig H (2008). «Levadopa: A Pharmacologic Miracle Four Decades Later». In Factor SA, Weiner WJ (eds.). Parkinson's Disease: Diagnosis and Clinical Management. Demos Medical Publishing. ISBN 978-1-934559-87-1 – via Google eBook.

clinchem.org

Hyland K, Clayton PT (December 1992). «Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology» (PDF). Clinical Chemistry. 38 (12): 2405–10. doi:10.1093/clinchem/38.12.2405. PMID 1281049. Արխիվացված է օրիգինալից (PDF) 2011-06-07-ին. Վերցված է 2008-10-16-ին.

doi.org

Cohen PA, Avula B, Katragunta K, Khan I (October 2022). «Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database». JAMA Neurology. 79 (10): 1085–1086. doi:10.1001/jamaneurol.2022.2184. PMC 9361182. PMID 35939305.
Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS (September 2008). «L-DOPA is an endogenous ligand for OA1». PLOS Biology. 6 (9): e236. doi:10.1371/journal.pbio.0060236. PMC 2553842. PMID 18828673.
Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, Kamiya M, Yamashita N, Suzuki T, Matsuzaki S, Endo I, Goshima Y (January 2014). «The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii». British Journal of Pharmacology. 171 (2): 403–14. doi:10.1111/bph.12459. PMC 3904260. PMID 24117106.
Polturak G, Breitel D, Grossman N, Sarrion-Perdigones A, Weithorn E, Pliner M, Orzaez D, Granell A, Rogachev I, Aharoni A (2016). «Elucidation of the first committed step in betalain biosynthesis enables the heterologous engineering of betalain pigments in plants». New Phytol. 210 (1): 269–283. doi:10.1111/nph.13796. PMID 26683006.
Martens J, Günther K, Schickedanz M (1986). «Resolution of Optical Isomers by Thin-Layer Chromatography: Enantiomeric Purity of Methyldopa». Arch. Pharm. 319 (6): 572–574. doi:10.1002/ardp.19863190618. S2CID 97903386.
Hardebo JE, Owman C (July 1980). «Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface». Annals of Neurology. 8 (1): 1–31. doi:10.1002/ana.410080102. PMID 6105837. S2CID 22874032.
Ovallath S, Sulthana B (2017). «Levodopa: History and Therapeutic Applications». Annals of Indian Academy of Neurology. 20 (3): 185–189. doi:10.4103/aian.AIAN_241_17. PMC 5586109. PMID 28904446.
Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M, և այլք: (Cochrane Movement Disorders Group) (February 2011). «Levodopa for restless legs syndrome». The Cochrane Database of Systematic Reviews. 2011 (2): CD005504. doi:10.1002/14651858.CD005504.pub2. PMC 8889887. PMID 21328278.
Broadley KJ (March 2010). «The vascular effects of trace amines and amphetamines». Pharmacology & Therapeutics. 125 (3): 363–375. doi:10.1016/j.pharmthera.2009.11.005. PMID 19948186.
Lindemann L, Hoener MC (May 2005). «A renaissance in trace amines inspired by a novel GPCR family». Trends in Pharmacological Sciences. 26 (5): 274–281. doi:10.1016/j.tips.2005.03.007. PMID 15860375.
Wang X, Li J, Dong G, Yue J (February 2014). «The endogenous substrates of brain CYP2D». European Journal of Pharmacology. 724: 211–218. doi:10.1016/j.ejphar.2013.12.025. PMID 24374199.
Rodgers KJ (March 2014). «Non-protein amino acids and neurodegeneration: the enemy within». Experimental Neurology. 253: 192–196. doi:10.1016/j.expneurol.2013.12.010. PMID 24374297. S2CID 2288729.
Hyland K, Clayton PT (December 1992). «Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology» (PDF). Clinical Chemistry. 38 (12): 2405–10. doi:10.1093/clinchem/38.12.2405. PMID 1281049. Արխիվացված է օրիգինալից (PDF) 2011-06-07-ին. Վերցված է 2008-10-16-ին.
Ito S, Kato T, Shinpo K, Fujita K (September 1984). «Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine». The Biochemical Journal. 222 (2): 407–11. doi:10.1042/bj2220407. PMC 1144193. PMID 6433900.
Waite JH, Andersen NH, Jewhurst S, Sun C (2005). «Mussel Adhesion: Finding the Tricks Worth Mimicking». J Adhesion. 81 (3–4): 1–21. doi:10.1080/00218460590944602. S2CID 136967853.
Giuri D, Ravarino P, Tomasini C (June 2021). «L-Dopa in small peptides: an amazing functionality to form supramolecular materials». Organic & Biomolecular Chemistry. 19 (21): 4622–4636. doi:10.1039/D1OB00378J. hdl:11585/840774. PMID 33978030. S2CID 234474122.
Fichman G, Adler-Abramovich L, Manohar S, Mironi-Harpaz I, Guterman T, Seliktar D, Messersmith PB, Gazit E (July 2014). «Seamless metallic coating and surface adhesion of self-assembled bioinspired nanostructures based on di-(3,4-dihydroxy-L-phenylalanine) peptide motif». ACS Nano. 8 (7): 7220–7228. doi:10.1021/nn502240r. PMC 4108209. PMID 24936704.
Fichman G, Guterman T, Adler-Abramovich L, Gazit E (August 2014). «The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies». Nanomaterials. 4 (3): 726–740. doi:10.3390/nano4030726. PMC 5304689. PMID 28344244.
Fichman G, Andrews C, Patel NL, Schneider JP (October 2021). «Antibacterial Gel Coatings Inspired by the Cryptic Function of a Mussel Byssal Peptide». Advanced Materials. 33 (40): e2103677. Bibcode:2021AdM....3303677F. doi:10.1002/adma.202103677. PMC 8492546. PMID 34423482.
Maity S, Nir S, Zada T, Reches M (October 2014). «Self-assembly of a tripeptide into a functional coating that resists fouling». Chemical Communications. 50 (76): 11154–11157. doi:10.1039/C4CC03578J. PMID 25110984.
Merims D, Giladi N (2008). «Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease». Parkinsonism & Related Disorders. 14 (4): 273–80. doi:10.1016/j.parkreldis.2007.09.007. PMID 17988927.
Dorszewska J, Prendecki M, Lianeri M, Kozubski W (February 2014). «Molecular Effects of L-dopa Therapy in Parkinson's Disease». Current Genomics. 15 (1): 11–7. doi:10.2174/1389202914666131210213042. PMC 3958954. PMID 24653659.
Ehringer H, Hornykiewicz O (December 1960). «[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]». Klinische Wochenschrift. 38 (24): 1236–9. doi:10.1007/BF01485901. PMID 13726012. S2CID 32896604.
Cotzias GC, Papavasiliou PS, Gellene R (July 1969). «L-dopa in parkinson's syndrome». The New England Journal of Medicine. 281 (5): 272. doi:10.1056/NEJM196907312810518. PMID 5791298.
Cotzias GC (March 1968). «L-Dopa for Parkinsonism». The New England Journal of Medicine. 278 (11): 630. doi:10.1056/nejm196803142781127. PMID 5637779.
Knowles WS (1983). «Asymmetric hydrogenation». Accounts of Chemical Research. 16 (3): 106–112. doi:10.1021/ar00087a006.
Knowles WS (March 1986). «Application of organometallic catalysis to the commercial production of L-DOPA». Journal of Chemical Education. 63 (3): 222. Bibcode:1986JChEd..63..222K. doi:10.1021/ed063p222.
Brilliant MH, Vaziri K, Connor TB, Schwartz SG, Carroll JJ, McCarty CA, Schrodi SJ, Hebbring SJ, Kishor KS, Flynn HW, Moshfeghi AA, Moshfeghi DM, Fini ME, McKay BS (March 2016). «Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration». The American Journal of Medicine. 129 (3): 292–8. doi:10.1016/j.amjmed.2015.10.015. PMC 4841631. PMID 26524704.
Fujii Y, Shibuya T, Yasuda T (1991). «L-3,4-Dihydroxyphenylalanine as an Allelochemical Candidate from Mucuna pruriens (L.) DC. var. utilis». Agricultural and Biological Chemistry. 55 (2): 617–618. doi:10.1080/00021369.1991.10870627.
Hsieh EJ, Liao SW, Chang CY, Tseng CH, Wang SL, Grillet L (2023). «L-DOPA induces iron accumulation in roots of Ipomoea aquatica and Arabidopsis thaliana in a pH-dependent manner». Botanical Studies. 64 (24): 617–618. Bibcode:2023BotSt..64...24H. doi:10.1186/s40529-023-00396-7. PMC 10449704. PMID 37620733.

drugs.com

«Lodosyn», Drugs, nd, Վերցված է 12 November 2012-ին

handle.net

hdl.handle.net

Giuri D, Ravarino P, Tomasini C (June 2021). «L-Dopa in small peptides: an amazing functionality to form supramolecular materials». Organic & Biomolecular Chemistry. 19 (21): 4622–4636. doi:10.1039/D1OB00378J. hdl:11585/840774. PMID 33978030. S2CID 234474122.

harvard.edu

ui.adsabs.harvard.edu

Fichman G, Andrews C, Patel NL, Schneider JP (October 2021). «Antibacterial Gel Coatings Inspired by the Cryptic Function of a Mussel Byssal Peptide». Advanced Materials. 33 (40): e2103677. Bibcode:2021AdM....3303677F. doi:10.1002/adma.202103677. PMC 8492546. PMID 34423482.
Knowles WS (March 1986). «Application of organometallic catalysis to the commercial production of L-DOPA». Journal of Chemical Education. 63 (3): 222. Bibcode:1986JChEd..63..222K. doi:10.1021/ed063p222.
Hsieh EJ, Liao SW, Chang CY, Tseng CH, Wang SL, Grillet L (2023). «L-DOPA induces iron accumulation in roots of Ipomoea aquatica and Arabidopsis thaliana in a pH-dependent manner». Botanical Studies. 64 (24): 617–618. Bibcode:2023BotSt..64...24H. doi:10.1186/s40529-023-00396-7. PMC 10449704. PMID 37620733.

inbrija.com

«Inbrija Prescribing Information» (PDF). Վերցված է February 14, 2019-ին.

laskerfoundation.org

«Lasker Award». 1969. Արխիվացված է օրիգինալից 2016-01-05-ին., accessed April 1, 2013

nih.gov

pubmed.ncbi.nlm.nih.gov

Cohen PA, Avula B, Katragunta K, Khan I (October 2022). «Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database». JAMA Neurology. 79 (10): 1085–1086. doi:10.1001/jamaneurol.2022.2184. PMC 9361182. PMID 35939305.
Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS (September 2008). «L-DOPA is an endogenous ligand for OA1». PLOS Biology. 6 (9): e236. doi:10.1371/journal.pbio.0060236. PMC 2553842. PMID 18828673.
Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, Kamiya M, Yamashita N, Suzuki T, Matsuzaki S, Endo I, Goshima Y (January 2014). «The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii». British Journal of Pharmacology. 171 (2): 403–14. doi:10.1111/bph.12459. PMC 3904260. PMID 24117106.
Polturak G, Breitel D, Grossman N, Sarrion-Perdigones A, Weithorn E, Pliner M, Orzaez D, Granell A, Rogachev I, Aharoni A (2016). «Elucidation of the first committed step in betalain biosynthesis enables the heterologous engineering of betalain pigments in plants». New Phytol. 210 (1): 269–283. doi:10.1111/nph.13796. PMID 26683006.
Hardebo JE, Owman C (July 1980). «Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface». Annals of Neurology. 8 (1): 1–31. doi:10.1002/ana.410080102. PMID 6105837. S2CID 22874032.
Ovallath S, Sulthana B (2017). «Levodopa: History and Therapeutic Applications». Annals of Indian Academy of Neurology. 20 (3): 185–189. doi:10.4103/aian.AIAN_241_17. PMC 5586109. PMID 28904446.
Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M, և այլք: (Cochrane Movement Disorders Group) (February 2011). «Levodopa for restless legs syndrome». The Cochrane Database of Systematic Reviews. 2011 (2): CD005504. doi:10.1002/14651858.CD005504.pub2. PMC 8889887. PMID 21328278.
Broadley KJ (March 2010). «The vascular effects of trace amines and amphetamines». Pharmacology & Therapeutics. 125 (3): 363–375. doi:10.1016/j.pharmthera.2009.11.005. PMID 19948186.
Lindemann L, Hoener MC (May 2005). «A renaissance in trace amines inspired by a novel GPCR family». Trends in Pharmacological Sciences. 26 (5): 274–281. doi:10.1016/j.tips.2005.03.007. PMID 15860375.
Wang X, Li J, Dong G, Yue J (February 2014). «The endogenous substrates of brain CYP2D». European Journal of Pharmacology. 724: 211–218. doi:10.1016/j.ejphar.2013.12.025. PMID 24374199.
Rodgers KJ (March 2014). «Non-protein amino acids and neurodegeneration: the enemy within». Experimental Neurology. 253: 192–196. doi:10.1016/j.expneurol.2013.12.010. PMID 24374297. S2CID 2288729.
Hyland K, Clayton PT (December 1992). «Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology» (PDF). Clinical Chemistry. 38 (12): 2405–10. doi:10.1093/clinchem/38.12.2405. PMID 1281049. Արխիվացված է օրիգինալից (PDF) 2011-06-07-ին. Վերցված է 2008-10-16-ին.
Ito S, Kato T, Shinpo K, Fujita K (September 1984). «Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine». The Biochemical Journal. 222 (2): 407–11. doi:10.1042/bj2220407. PMC 1144193. PMID 6433900.
Giuri D, Ravarino P, Tomasini C (June 2021). «L-Dopa in small peptides: an amazing functionality to form supramolecular materials». Organic & Biomolecular Chemistry. 19 (21): 4622–4636. doi:10.1039/D1OB00378J. hdl:11585/840774. PMID 33978030. S2CID 234474122.
Fichman G, Adler-Abramovich L, Manohar S, Mironi-Harpaz I, Guterman T, Seliktar D, Messersmith PB, Gazit E (July 2014). «Seamless metallic coating and surface adhesion of self-assembled bioinspired nanostructures based on di-(3,4-dihydroxy-L-phenylalanine) peptide motif». ACS Nano. 8 (7): 7220–7228. doi:10.1021/nn502240r. PMC 4108209. PMID 24936704.
Fichman G, Guterman T, Adler-Abramovich L, Gazit E (August 2014). «The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies». Nanomaterials. 4 (3): 726–740. doi:10.3390/nano4030726. PMC 5304689. PMID 28344244.
Fichman G, Andrews C, Patel NL, Schneider JP (October 2021). «Antibacterial Gel Coatings Inspired by the Cryptic Function of a Mussel Byssal Peptide». Advanced Materials. 33 (40): e2103677. Bibcode:2021AdM....3303677F. doi:10.1002/adma.202103677. PMC 8492546. PMID 34423482.
Maity S, Nir S, Zada T, Reches M (October 2014). «Self-assembly of a tripeptide into a functional coating that resists fouling». Chemical Communications. 50 (76): 11154–11157. doi:10.1039/C4CC03578J. PMID 25110984.
Merims D, Giladi N (2008). «Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease». Parkinsonism & Related Disorders. 14 (4): 273–80. doi:10.1016/j.parkreldis.2007.09.007. PMID 17988927.
Dorszewska J, Prendecki M, Lianeri M, Kozubski W (February 2014). «Molecular Effects of L-dopa Therapy in Parkinson's Disease». Current Genomics. 15 (1): 11–7. doi:10.2174/1389202914666131210213042. PMC 3958954. PMID 24653659.
Ehringer H, Hornykiewicz O (December 1960). «[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]». Klinische Wochenschrift. 38 (24): 1236–9. doi:10.1007/BF01485901. PMID 13726012. S2CID 32896604.
Birkmayer W, Hornykiewicz O (November 1961). «[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]». Wiener Klinische Wochenschrift. 73: 787–8. PMID 13869404.
Cotzias GC, Papavasiliou PS, Gellene R (July 1969). «L-dopa in parkinson's syndrome». The New England Journal of Medicine. 281 (5): 272. doi:10.1056/NEJM196907312810518. PMID 5791298.
Cotzias GC (March 1968). «L-Dopa for Parkinsonism». The New England Journal of Medicine. 278 (11): 630. doi:10.1056/nejm196803142781127. PMID 5637779.
Brilliant MH, Vaziri K, Connor TB, Schwartz SG, Carroll JJ, McCarty CA, Schrodi SJ, Hebbring SJ, Kishor KS, Flynn HW, Moshfeghi AA, Moshfeghi DM, Fini ME, McKay BS (March 2016). «Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration». The American Journal of Medicine. 129 (3): 292–8. doi:10.1016/j.amjmed.2015.10.015. PMC 4841631. PMID 26524704.
Hsieh EJ, Liao SW, Chang CY, Tseng CH, Wang SL, Grillet L (2023). «L-DOPA induces iron accumulation in roots of Ipomoea aquatica and Arabidopsis thaliana in a pH-dependent manner». Botanical Studies. 64 (24): 617–618. Bibcode:2023BotSt..64...24H. doi:10.1186/s40529-023-00396-7. PMC 10449704. PMID 37620733.

ncbi.nlm.nih.gov

Cohen PA, Avula B, Katragunta K, Khan I (October 2022). «Levodopa Content of Mucuna pruriens Supplements in the NIH Dietary Supplement Label Database». JAMA Neurology. 79 (10): 1085–1086. doi:10.1001/jamaneurol.2022.2184. PMC 9361182. PMID 35939305.
Lopez VM, Decatur CL, Stamer WD, Lynch RM, McKay BS (September 2008). «L-DOPA is an endogenous ligand for OA1». PLOS Biology. 6 (9): e236. doi:10.1371/journal.pbio.0060236. PMC 2553842. PMID 18828673.
Hiroshima Y, Miyamoto H, Nakamura F, Masukawa D, Yamamoto T, Muraoka H, Kamiya M, Yamashita N, Suzuki T, Matsuzaki S, Endo I, Goshima Y (January 2014). «The protein Ocular albinism 1 is the orphan GPCR GPR143 and mediates depressor and bradycardic responses to DOPA in the nucleus tractus solitarii». British Journal of Pharmacology. 171 (2): 403–14. doi:10.1111/bph.12459. PMC 3904260. PMID 24117106.
Ovallath S, Sulthana B (2017). «Levodopa: History and Therapeutic Applications». Annals of Indian Academy of Neurology. 20 (3): 185–189. doi:10.4103/aian.AIAN_241_17. PMC 5586109. PMID 28904446.
Scholz H, Trenkwalder C, Kohnen R, Riemann D, Kriston L, Hornyak M, և այլք: (Cochrane Movement Disorders Group) (February 2011). «Levodopa for restless legs syndrome». The Cochrane Database of Systematic Reviews. 2011 (2): CD005504. doi:10.1002/14651858.CD005504.pub2. PMC 8889887. PMID 21328278.
Ito S, Kato T, Shinpo K, Fujita K (September 1984). «Oxidation of tyrosine residues in proteins by tyrosinase. Formation of protein-bonded 3,4-dihydroxyphenylalanine and 5-S-cysteinyl-3,4-dihydroxyphenylalanine». The Biochemical Journal. 222 (2): 407–11. doi:10.1042/bj2220407. PMC 1144193. PMID 6433900.
Fichman G, Adler-Abramovich L, Manohar S, Mironi-Harpaz I, Guterman T, Seliktar D, Messersmith PB, Gazit E (July 2014). «Seamless metallic coating and surface adhesion of self-assembled bioinspired nanostructures based on di-(3,4-dihydroxy-L-phenylalanine) peptide motif». ACS Nano. 8 (7): 7220–7228. doi:10.1021/nn502240r. PMC 4108209. PMID 24936704.
Fichman G, Guterman T, Adler-Abramovich L, Gazit E (August 2014). «The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies». Nanomaterials. 4 (3): 726–740. doi:10.3390/nano4030726. PMC 5304689. PMID 28344244.
Fichman G, Andrews C, Patel NL, Schneider JP (October 2021). «Antibacterial Gel Coatings Inspired by the Cryptic Function of a Mussel Byssal Peptide». Advanced Materials. 33 (40): e2103677. Bibcode:2021AdM....3303677F. doi:10.1002/adma.202103677. PMC 8492546. PMID 34423482.
Dorszewska J, Prendecki M, Lianeri M, Kozubski W (February 2014). «Molecular Effects of L-dopa Therapy in Parkinson's Disease». Current Genomics. 15 (1): 11–7. doi:10.2174/1389202914666131210213042. PMC 3958954. PMID 24653659.
Brilliant MH, Vaziri K, Connor TB, Schwartz SG, Carroll JJ, McCarty CA, Schrodi SJ, Hebbring SJ, Kishor KS, Flynn HW, Moshfeghi AA, Moshfeghi DM, Fini ME, McKay BS (March 2016). «Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration». The American Journal of Medicine. 129 (3): 292–8. doi:10.1016/j.amjmed.2015.10.015. PMC 4841631. PMID 26524704.
Hsieh EJ, Liao SW, Chang CY, Tseng CH, Wang SL, Grillet L (2023). «L-DOPA induces iron accumulation in roots of Ipomoea aquatica and Arabidopsis thaliana in a pH-dependent manner». Botanical Studies. 64 (24): 617–618. Bibcode:2023BotSt..64...24H. doi:10.1186/s40529-023-00396-7. PMC 10449704. PMID 37620733.

northwestern.edu

biomaterials.bme.northwestern.edu

«Mussel Adhesive Protein Mimetics». Արխիվացված է օրիգինալից 2006-05-29-ին.

q1medicare.com

«Medicare D». Medicare. 2014. Վերցված է 12 November 2015-ին.

sciencedaily.com

«Study Reveals Details Of Mussels' Tenacious Bonds». Science Daily. Aug 16, 2006. Վերցված է Sep 30, 2013-ին.

semanticscholar.org

api.semanticscholar.org

Martens J, Günther K, Schickedanz M (1986). «Resolution of Optical Isomers by Thin-Layer Chromatography: Enantiomeric Purity of Methyldopa». Arch. Pharm. 319 (6): 572–574. doi:10.1002/ardp.19863190618. S2CID 97903386.
Hardebo JE, Owman C (July 1980). «Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface». Annals of Neurology. 8 (1): 1–31. doi:10.1002/ana.410080102. PMID 6105837. S2CID 22874032.
Rodgers KJ (March 2014). «Non-protein amino acids and neurodegeneration: the enemy within». Experimental Neurology. 253: 192–196. doi:10.1016/j.expneurol.2013.12.010. PMID 24374297. S2CID 2288729.
Waite JH, Andersen NH, Jewhurst S, Sun C (2005). «Mussel Adhesion: Finding the Tricks Worth Mimicking». J Adhesion. 81 (3–4): 1–21. doi:10.1080/00218460590944602. S2CID 136967853.
Giuri D, Ravarino P, Tomasini C (June 2021). «L-Dopa in small peptides: an amazing functionality to form supramolecular materials». Organic & Biomolecular Chemistry. 19 (21): 4622–4636. doi:10.1039/D1OB00378J. hdl:11585/840774. PMID 33978030. S2CID 234474122.
Ehringer H, Hornykiewicz O (December 1960). «[Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]». Klinische Wochenschrift. 38 (24): 1236–9. doi:10.1007/BF01485901. PMID 13726012. S2CID 32896604.

web.archive.org

Hyland K, Clayton PT (December 1992). «Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology» (PDF). Clinical Chemistry. 38 (12): 2405–10. doi:10.1093/clinchem/38.12.2405. PMID 1281049. Արխիվացված է օրիգինալից (PDF) 2011-06-07-ին. Վերցված է 2008-10-16-ին.
«Mussel Adhesive Protein Mimetics». Արխիվացված է օրիգինալից 2006-05-29-ին.
«Lasker Award». 1969. Արխիվացված է օրիգինալից 2016-01-05-ին., accessed April 1, 2013

wisc.edu

chem.wisc.edu

«Synthetic scheme for total synthesis of DOPA, L- (Monsanto)». UW Madison, Department of Chemistry. Վերցված է Sep 30, 2013-ին.